Description

PA007162.m1DA: Recombinant Anti-mouse PD-1 Monoclonal Antibody (RMP1-14.1), Mouse IgG1-D265A Kappa, In Vivo Grade

References for anti-mouse PD-1 antibody(RMP1-14):

1、Th2 cell-intrinsic hypo-responsiveness determines susceptibility to helminth infection.
van der Werf, N., et al. PLoS Pathog. 2013 Mar;9(3):e1003215. doi: 10.1371/journal.ppat.1003215. PMID: 23516361
We further demonstrate that we can therapeutically manipulate the intrinsic functional quality of hypo-responsive Th2 cells via the PD-1/PD-L2 co-inhibitory pathway to reawaken them and enhance resistance to infection. …The onset of hypo-responsiveness was accompanied by increased expression of PD-1 by IL-4gfp+ Th2 cells, and in vivo PD-1 blockade led to increased resistance to infection and a long-term increase in Th2 cell functional quality. …To investigate whether L. sigmodontis-induced Th2 cell hypo-responsiveness was associated with PD-1 co-inhibition, the expression of PD-1 by IL-4gfp+ Th2 cells was assessed. …To test the hypothesis that blocking PD-1 signalling on the hypo-responsive Th2 cells in vitro could re-activate their functional responsiveness, IL-4gfp+ Th2 cells were purified from the PC 60 d post-L. …There was a significant reduction in the number of healthy uterine eggs within female parasites from PD-1 treated mice at d 60 pi.
Tags: anti-mouse PD-1 RMP1-14 antibody in mouse tumor model; function of recombinant anti-mouse PD-1 RMP1-14

2、Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells.
John, L. B., et al. Clin Cancer Res. 2013 Oct 15;19(20):5636-46. doi: 10.1158/1078-0432.CCR-13-0458. PMID: 23873688
In this study, we show that blockade of the PD-1 immunosuppressive pathway using an anti-PD-1 antibody can significantly enhance the antitumor efficacy of genetically modified T cells expressing a chimeric antigen receptor (CAR). …The PD-1 pathway has emerged as another promising target for cancer therapy. …Engagement of the PD-1/PD-L1 pathway results in the phosphorylation of tyrosine-based motifs in the cytoplasmic tail of the PD-1 inhibitory receptor, which promotes the recruitment of SHP2 phosphatase leading to dephosphorylation of PI3K. …Recent trials using a fully human IgG4 PD-1 monocloncal antibody (mAb; BMS-936558) have reported durable clinical responses in patients with advanced melanoma, non?small cell lung, renal cell, as well as hematologic malignancies. …Hence, in this study, we hypothesized that CAR T-cell therapy in combination with PD-1 blockade may overcome PD-L1+ tumor immunosuppression, thereby leading to improved therapeutic efficacy.
Tags: recombinant anti-mouse PD-1 RMP1-14 mAb of low endotoxin; clone RMP1-14 of anti-mouse PD-1 antibody

3、Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.
Holmgaard, R. B., et al. J Exp Med. 2013 Jul 1;210(7):1389-402. doi: 10.1084/jem.20130066. PMID: 23752227
This was also observed with antibodies targeting PD-1?PD-L1 and GITR. …Along these lines, we demonstrate that inhibition/absence of IDO in combination with therapies targeting immune checkpoints such as CTLA-4, PD-1/PD-L1, and GITR synergize to control tumor outgrowth and enhance overall survival in different tumor models. …In contrast to effector T cells, there was no significant increase in proliferation or up-regulation of PD-1 or ICOS by the tumor-infiltrating T reg cells with anti?CTLA-4 therapy. …Anti?PD-1/PD-L1 treatment delayed tumor progression in B16F10-bearing WT mice, but resulted in only modest improvement in survival. …However, anti?PD-1/PD-L1 treatment in IDO?/? mice resulted in significantly reduced tumor growth and improved survival.
Tags: bioactivity of anti-mouse PD-1 RMP1-14; recombinant anti-mouse PD-1 RMP1-14 of low endotoxin

Related Recombinant IgG Reference Antibodies:
Recombinant Mouse IgG1 Isotype Control Antibody and Mutants, In vivo Grade
Recombinant Mouse IgG2a Isotype Control Antibody and Mutants, In vivo Grade
Recombinant Mouse IgG2c Isotype Control Antibody and Mutants, In vivo Grade
Recombinant Rat IgG2a Isotype Control Antibody, In vivo Grade

Syd Labs provides the following anti-mouse PD-L1 / PD-1 antibodies:
Recombinant anti-mouse PD1 antibodies (Clone 29F.1A12.1), In vivo grade
Recombinant anti-mouse PD-1 antibodies (Clone RMP1-14.1), In vivo grade
Recombinant anti-mouse PD-L1 antibodies (Clone 10F.9G2.1), In vivo grade
Recombinant anti-mouse PD-1 / PD-1 bispecific antibodies (Clone RMP1-14.1 / 29F.1A12.1), In vivo grade
Recombinant anti-mouse PD-1 / PD-1 bispecific antibodies (Clone 29F.1A12.1 / RMP1-14.1), In vivo grade
Recombinant anti-mouse PD-1 / PD-L1 bispecific antibodies (Clone RMP1-14.1 / 10F.9G2.1), In vivo grade
Recombinant anti-mouse PD-L1 / PD-1 bispecific antibodies (Clone 10F.9G2.1 / RMP1-14.1), In vivo grade
Recombinant anti-mouse PD-1 / PD-L1 bispecific antibodies (Clone 29F.1A12.1 / 10F.9G2.1), In vivo grade
Recombinant anti-mouse PD-L1 / PD-1 bispecific antibodies (Clone 10F.9G2.1 / 29F.1A12.1), In vivo grade

Ushelf Advisor

Powered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments.

Q: How does the affinity and blocking ability of Recombinant Anti-mouse PD-1 Antibody RMP1-14 compare to other clones?

The Recombinant Anti-mouse PD-1 Antibody RMP1-14 is a widely used clone for in vivo PD-1 blockade in mouse models, but literature comparisons highlight differences in affinity and blocking potency relative to other clones like 29F.1A12 and J43.

• Affinity: Studies show that the Recombinant rmp1-14 antibody binds to mouse PD-1 with an apparent affinity of approximately 28.8 nM, which is about 100-fold weaker than the 0.42 nM affinity of clone 29F.1A12. Clone J43 exhibits intermediate binding strength, though direct quantitative comparisons to RMP1-14 are less detailed, often placing it between 29F.1A12 and RMP1-14 in overall avidity.
• Blocking Ability: The Recombinant Anti-mouse PD-1 Antibody RMP1-14 effectively blocks PD-1 binding to PD-L1 and PD-L2, with IC50 values of 3.23 μg/mL and 4.05 μg/mL, respectively, but requires higher concentrations than 29F.1A12 (IC50 of 0.036 μg/mL for PD-L1 and 0.034 μg/mL for PD-L2), again indicating ~100-fold lower potency. Compared to J43, RMP1-14 shows similar or slightly stronger blocking in some assays, though both are outperformed by 29F.1A12 in reversing PD-1-mediated T-cell inhibition. Notably, RMP1-14 also displays dual functionality with some agonist activity at high PD-1 expression levels, unlike the pure blocking profile of 29F.1A12.

Overall, while the Recombinant Anti-mouse PD-1 Antibody RMP1-14 is effective for PD-1 blockade, 29F.1A12 is generally superior in affinity and blocking efficiency, making it a closer surrogate for high-affinity human PD-1 therapeutics. Researchers may prefer RMP1-14 for scenarios requiring moderate-affinity binding to target high-PD-1-expressing tissues.

Q: Is Recombinant Anti-mouse PD-1 Antibody RMP1-14 immunogenic or prone to hypersensitivity in repeated mouse injections?

The Recombinant Anti-mouse PD-1 Antibody RMP1-14, originally derived from a rat hybridoma, has been associated with immunogenicity concerns in its non-murinized form, but recombinant versions are designed to mitigate these issues.

• Immunogenicity of Original Rat-Derived Version: The rat-origin sequences in the original Recombinant rmp1-14 antibody render it immunogenic upon injection in mice, often triggering host anti-rat immune responses that can compromise antibody performance or lead to immunogenic events with repeated administrations. This is particularly noted for PD-1/PD-L1 axis-targeting antibodies, where repeated injections in tumor-bearing mice have induced fatal xenogeneic hypersensitivity reactions.
• Hypersensitivity Risks: In a murine model of breast cancer, repeated administration of xenogeneic (rat-derived) Recombinant Anti-mouse PD-1 Antibody RMP1-14 led to fatal hypersensitivity, highlighting the risks in syngeneic tumor models with multiple doses. These reactions are attributed to the foreign rat sequences provoking immune responses.
• Mitigation in Recombinant Murinized Formats: To address these issues, recombinant versions like the Mouse IgG1-D265A Kappa (In Vivo Grade) of Recombinant Anti-mouse PD-1 Antibody RMP1-14 incorporate murinized variable regions and mouse constant regions, reducing immunogenicity and hypersensitivity risks. For instance, fully murine or murinized clones show improved survival and tumor regression compared to the original RMP1-14 in repeated dosing scenarios, with lower rates of adverse immune reactions.

Overall, while the original rat-derived Recombinant rmp1-14 antibody is prone to immunogenicity and hypersensitivity in repeated mouse injections, the recombinant Mouse IgG1-D265A version is engineered for reduced risks, making it more suitable for in vivo studies.